adenosine monophosphate has been researched along with montelukast in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (88.89) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Dempsey, OJ; Lipworth, BJ; Mistry, C; Sims, EJ; Wilson, AM | 1 |
| Dempsey, OJ; Lipworth, BJ; Sims, EJ; Wilson, AM | 1 |
| Arshad, H; Holgate, ST; Jeffs, JA; Jennison, S; Rorke, S; Sampson, AP | 1 |
| Bates, CE; Currie, GP; Haggart, K; Lee, DK; Lipworth, BJ | 1 |
| Anderson, SD; Brannan, JD; Currie, GP; Fowler, SJ; Haggart, K; Lee, DK; Lipworth, BJ; Wilson, AM | 1 |
| Haggart, K; Jackson, CM; Lee, DK; Lipworth, BJ | 1 |
| Fardon, EJ; Fardon, TC; Hodge, MR; Lipworth, BJ | 1 |
| Albisetti, M; Johannes, W; Knauer, N; Lehmann, A; Moeller, A; Rochat, M | 1 |
| Dey, M; Singh, RK | 1 |
1 review(s) available for adenosine monophosphate and montelukast
| Article | Year |
|---|---|
Possible Therapeutic Potential of Cysteinyl Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19.
Topics: Acetates; Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cyclopropanes; Humans; Leukotriene Antagonists; Quinolines; Receptors, Leukotriene; Sulfides | 2021 |
7 trial(s) available for adenosine monophosphate and montelukast
| Article | Year |
|---|---|
Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids.
Topics: Acetates; Adenosine Monophosphate; Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Cross-Over Studies; Cyclopropanes; Drug Therapy, Combination; Glucocorticoids; Humans; Leukotriene Antagonists; Quinolines; Respiratory Function Tests; Salmeterol Xinafoate; Single-Blind Method; Sulfides; Treatment Outcome | 2000 |
Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids.
Topics: Acetates; Adenosine Monophosphate; Administration, Inhalation; Administration, Topical; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Breath Tests; Bronchial Provocation Tests; Bronchodilator Agents; Cross-Over Studies; Cyclopropanes; Eosinophils; Female; Glucocorticoids; Humans; Leukocyte Count; Leukotriene Antagonists; Male; Nitric Oxide; Peak Expiratory Flow Rate; Quinolines; Respiratory Mechanics; Salmeterol Xinafoate; Single-Blind Method; Steroids; Sulfides | 2001 |
Role of cysteinyl leukotrienes in adenosine 5'-monophosphate induced bronchoconstriction in asthma.
Topics: Acetates; Adenosine Monophosphate; Adult; Anti-Asthmatic Agents; Asthma; Bronchoconstriction; Cross-Over Studies; Cyclopropanes; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Leukotriene Antagonists; Leukotriene E4; Male; Membrane Proteins; Middle Aged; Quinolines; Receptors, Leukotriene; Sulfides | 2002 |
Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma.
Topics: Acetates; Adenosine Monophosphate; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Biomarkers; Bronchial Provocation Tests; Cross-Over Studies; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Fluticasone; Forced Expiratory Volume; Humans; Leukotriene Antagonists; Male; Middle Aged; Quinolines; Salmeterol Xinafoate; Severity of Illness Index; Sulfides; Treatment Outcome | 2003 |
Effects of mediator antagonism on mannitol and adenosine monophosphate challenges.
Topics: Acetates; Adenosine Monophosphate; Adult; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchoconstrictor Agents; Cross-Over Studies; Cyclopropanes; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Leukotriene Antagonists; Loratadine; Male; Mannitol; Middle Aged; Quinolines; Sulfides; Time Factors | 2003 |
Repeated dosing effects of mediator antagonists in inhaled corticosteroid-treated atopic asthmatic patients.
Topics: Acetates; Adenosine Monophosphate; Administration, Inhalation; Adrenal Cortex Hormones; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Cross-Over Studies; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Peak Expiratory Flow Rate; Quinolines; Respiratory Hypersensitivity; Sulfides; Terfenadine; Treatment Outcome | 2004 |
Effects of montelukast on subjective and objective outcome measures in preschool asthmatic children.
Topics: Acetates; Adenosine Monophosphate; Anti-Asthmatic Agents; Asthma; Child, Preschool; Cyclopropanes; Exhalation; Female; Forced Expiratory Volume; Humans; Infant; Leukotriene Antagonists; Male; Nitric Oxide; Prospective Studies; Quinolines; Respiratory Function Tests; Severity of Illness Index; Spirometry; Sulfides; Treatment Outcome; Vital Capacity | 2008 |
1 other study(ies) available for adenosine monophosphate and montelukast
| Article | Year |
|---|---|
Comparative cutoff points for adenosine monophosphate and methacholine challenge testing.
Topics: Acetates; Adenosine Monophosphate; Administration, Inhalation; Adrenal Cortex Hormones; Anti-Asthmatic Agents; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchoconstrictor Agents; Cyclopropanes; Forced Expiratory Volume; Humans; Methacholine Chloride; Quinolines; Retrospective Studies; Sulfides | 2004 |